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1. Introduction 
The recent discovery by Luft and associates [l] 
and by Dubois [2] of somatostatin-containing islet 
cells, subsequently identified as D-cells [3-51, has 
opened a new phase in the physiology and patho- 
physiology of the endocrine pancreas. It is,now 
recognized that diabetes resulting from a deficiency 
of insulin-secreting cells, such as human juvenile type 
diabetes and streptozotocin diabetes in rats, is 
characterized by an apparent increase in somatostatin- 
containing D-cells per islet [6] and that the content 
of immunoassayable somatostatin in the islets of such 
rats is high [7]. However, it has not been determined 
if these abnormalities in the islets are reflected by 
hypersomatostatinemia - indeed, it is not known if 
under normal circumstances omatostatin is released 
into the circulation from those tissues in which its 
presence has been demonstrated [8,9]. In this study, 
we attemped to determine, first, if the levels of 
immunoreactive somatostatin-like material (IRS) in 
the venous plasma of organs with a substantial 
somatostatin content are higher than in peripheral 
venous plasma and, second, if hypersomatostatinemia 
is present in dogs with alloxan-induced deficiency of 
B-cells. 
2. Materials and methods 
We employed a modification of the radioimmuno- 
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assay of Arimura et al. [lo] , using a double antibody 
system with R-l 01 antisomatostatin serum of 
Arimura and a goat anti-rabbit globulin. To prevent 
damage of the ‘251-labeled tyrl-somatostatin during 
the incubation [ 1 l] , dog plasma was collected in 
tubes containing 1000 KalGkrein inhibitor units 
(KIU) of Trasylol and 1.2 mg EDTA/ml whole 
blood, and an additional 200 kIU were present per 
ml reaction mixture. With this assay, recovery of 
synthetic somatostatin incubated in canine plasma 
for 3 h was 88%. The minimum sensitivity of the 
assay was 50 pg/ml; above this level, differences of 
30 pglml could be measured with 95% confidence. 
The coefficient of variation within and between 
plasma assays was 15% and 3 l%, respectively. Because 
dilution slopes of plasma specimens with a high 
endogenous IRS level were slightly less steep than 
those obtained with hypersomatostatinemic plasma 
collected during the intravenous infusion of synthetic 
somatostatin, endogenous IRS levels were expressed 
as ‘pg equiv./ml’ rather than as pg/ml. Insulin and 
glucagon (IRG) were measured by modification of 
previously described technics [ 12,131. 
3. Results 
To determine the ability of the assay system to 
detect plasma increments of exogenous somatostatin, 
we infused synthetic somatostatin into conscious 
dogs at a rate of 50 ng/min, 100 ng/min, and 250 
ng/min for 30 min. The mean IRS of three plasma 
specimens obtained during each infusion period 
increased above the preinfusion baseline value of 
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96.2 + 11.2 pg/ml by 61.7 f 3.3 pg/ml during 
the 50 ng/min infusion, 85.0 + 13.2 pg/ml during the 
100 ng/min infusion, and 260.0 f 20.8 pg/ml during 
the 250 ng/min infusion. 
We next compared the plasma IRS levels of venous 
plasma specimens obtained in five anesthetized dogs 
from the effluent of organs known to have a high 
tissue concentration of immunoreactive somatostatin 
[8,9] with those of the inferior vena cava before and 
during the infusion of glucose. IRS measurements 
were at all times significantly higher in pancreatico- 
duodenal vein plasma than in plasma obtained 
simultaneously from the inferior vena cava (fig. 1). 
Although mean IRS levels were higher in the short 
gastric vein than in the inferior vena cava, the 
differences were not significant. In the gastroepiploic 
and mesenteric venous plasma, IRS levels were 
approximately the same as in the inferior vena cava. 
Intravenous infusion of glucose at a rate of 1 g/kg 
per h caused a significant increase in IRS concentra- 
tion only in the pancreaticoduodenal vein (tig.1). 
In six conscious dogs with an indwelling portal 
vein catheter, portal vein IRS levels were also con- 
sistently higher than in crural vein plasma (table 1). 
We measured fasting IRS levels in plasma obtained 
from the crural vein of conscious alloxan diabetic 
dogs fasted for 20 h and deprived of insulin for 40 h, 
and once again in these dogs during their usual diet 
and insulin treatment, which consisted of 8-16 U of 
NPH insulin twice daily. Following insulin deprivation 
and prolonged fast, their IRS levels averaged 
285 + 22.8 pg equiv./ml, significantly greater 
@<O.OOl) than the mean IRS of 159 + 9.9 pg 
equiv./ml in the same dogs when they were receiving 
insulin. The IRS levels of both treated and untreated 
animals were significantly greater than the 119 _+ 7.6 
pg equiv./ml average of a group of 12 conscious 
normal dogs @<O.OOS and p<O.OOl) (table 1). 
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4. Discussion 
These results, among the first reported measure- 
ments of immunoreactive somatostatin or somato- 
statin-like material in plasma [ 11,141, reveal a gradient 
of IRS only across the pancreas and the gastric fundus, 
but the latter gradient was not statistically significant. 
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Fig.1. Immunoreactive somatostatin (IRS) concentration in the pancreatic, short gastric , gastroepiploic, and mesenteric vein 
plasma and in inferior vena caval plasma before and during intravenous glucose infusion in five anesthetized dogs. (o) Represents 
significance of at least p<O.O5 above the mean of the baseline values. Asteriks indicate a statistical significance of at least 
p<O.O5 above the mean inferior vena caval level. 
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Table 1 
Plasma somatostatin (IRS), glucose, glucagon (IRG), and insulin (IRI) levels in conscious normal and 
alloxan diabetic dogs 
Normal dogs 
Peripheral vein 
(N= 12) 
Portal vein 
(N=6) 
Alloxan diabetic dogs (peripheral vein) 
Insulin deprived Insulin treated 
(N= 8) (N= 7) 
Glucose 76.3 f 1.9 80.9 ? 3.0 320.0 * 14.7 250.0 +_ 14.7 
(mg/dH 
IRI 11.4 f 1.1 11.5 f- 0.8 8.4 +_ 0.7 11.8 * 1.2 
(pU/mH 
IRG 83.5 ? 7.2 248.6 ?; 28.2a 180.6 f 23.1b 149.0 * 13.9a 
@/ml) 
IRS 119.7 ?- 7.6 275.1 5 12.ga 284.6 f 22.8a,d 159.2 * 9.9c 
(pg equiv./ml) 
a p<O.OOl versus normal dogs, peripheral vein level 
bp<O.Ol versus normal dogs, peripheral vein level 
’ p<O.OOS versus normal dogs, peripheral vein level 
dp<O.OOl versus insulin treated alloxan diabetic dogs 
Values are means f SEM 
This would suggest hat the pancreas is a major contri- 
butor to the circulating IRS. The demonstration of 
increased pancreaticoduodenal vein IRS levels during 
glucose infusion confirms in vitro studies showing a 
stimulatory effect of glucose upon pancreatic IRS 
release [IS-I 71 . 
The study also demonstrates ignificantly increased 
fasting plasma IRS levels in insulin-deprived and, to 
a less degree, insulin-treated alloxan diabetic dogs. 
The latter finding would tit with earlier demonstra- 
tions of increased tissue IRS levels and IRS-containing 
D-cells in other forms of diabetes in which B-cells are 
deficient [6,7]. 
In view of the possible endocrine roles of pancreatic 
somatostatin [ 18,191, these findings may be of 
physiologic and pathophysiologic significance. 
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